Pfizer sues Texas agency over leak of drug prices
November 21, 2016Medical Communications, Sales and Marketing Drug pricing, Pfizer, US, texas
Pfizer has sued Texas’ Health and Human Services Commission, after it claimed the agency violated state and federal law by …
China conducts first gene-editing human trial
November 21, 2016Research and Development, Sales and Marketing China, DNA, cas9, crispr
China has used Crispr/Cas9 gene-editing technology to edit the DNA of a human subject, suffering from metastatic lung cancer. This …
GSK 18 months ahead of the game with three-drug inhaler
November 21, 2016Medical Communications, Sales and Marketing GSK, Innoviva, chronic obstructive pulmonary disease
GlaxoSmithKline, alongside its partner Innoviva, have filed a regulatory submission with the FDA for its treatment for chronic obstructive pulmonary …
Teva’s drug to replace chemotherapy in acute leukaemia
November 21, 2016Medical Communications, Sales and Marketing Teva, chemotherapy, first line, first-line, leukaemia
Teva Pharmaceutical announced that their drug Trisenox has been given approval from the European Commission to become the first line …
Novartis in $665 million deal for Selexys
November 21, 2016Sales and Marketing Novartis, SelG1, selexys
Novartis have confirmed the acquisition of Selexys Pharmaceuticals, after Selexys received positive results from a Phase II trial. Novartis had …
Top Ten most popular articles on Pharmafile.com this week
November 18, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, Crohn's, Janssen, otezla, top ten
While the world is still reeling from the US presidential election results; it’s business as usual for the pharma industry; …
GSK/J&J release how their drug measures up against Humira
November 18, 2016Medical Communications, Research and Development GSK, Humira, Janssen, Johnson & Johnson, sirukumab
GlaxoSmithKline and Janssen, part of Johnson & Johnson, released the results of their two Phase III trials exploring treatment options …
Former Valeant executive and Philidor CEO charged with fraud
November 18, 2016Medical Communications, Sales and Marketing Philidor, Valeant, Valeant Pharmaceuticals, fraud
Gary Tanner, former executive, and Andrew Davenport, ex-CEO of Philidor, have been arrested and charged with fraud. Preet Bharara, US …
NICE thumbs up for BMS leukaemia treatment
November 18, 2016Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, NICE, Sprycel, chronic myeloid leukaemia
Bristol-Myers Squibb has announced that NICE have given a Final Appraisal Determination recommending Sprycel (dasatinib) for the treatment of chronic …
New healthcare app aims to improve patient adherence
November 17, 2016Medical Communications, Sales and Marketing Echo, app, patient adherence, smartphone
The newly released app, named Echo, was developed by former Apple executive Dr Sai Lakshmi and former LloydsPharmacy executive Stephen …
Japan to slash Opdivo costs by 50%
November 17, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Japan, opdivo
Japan’s health ministry has announced it is to slash the price of Bristol-Myers Squibb’s Opdivo by 50% in the country …
Amgen boosted in race to market for migraine drug
November 17, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Novartis, erenumab, migraine, phase III
Amgen released positive results from their second Phase III trial for experimental migraine drug, known as erenumab, which it is …
NICE rules Shire’s Onivyde not cost effective
November 17, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, NICE, Onivyde, Shire
Shire’s Onivyde has been determined by NICE as not cost effective, in draft guidance, despite adding on average two months …
NICE approves Roche’s Perjeta for breast cancer
November 16, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, Perjeta, Roche, breast cancer
NICE has announced its approval of Roche’s Perjeta (pertuzumab) as a neoadjuvant treatment of HER2-positive, locally advanced, inflammatory or early-stage …
Myelofibrosis market to increase to be worth over $1 billion by 2025
November 16, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, US, myelofibrosis
The myelofibrosis market is expected to grow from $545.2 million in 2015 to $1.02 billion by 2025, almost doubling in …
Surprising number of parents agree to use of placebos in children
November 16, 2016Medical Communications, Research and Development Placebo, children
A study by Boston Children’s Hospital found that parents recognised that placebos are a vital part of research and that …
Real world evidence: a reality check for pharma?
November 16, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing real world evidence
Rising demands on the industry has pharma firms calling for a more-effective, fit-for-purpose methodology for generating clinical data. Could the …
Powerful new data for MSD’s bladder cancer drug stops trial early
November 16, 2016Research and Development MSD, pembrolizumab
MSD has released new data which reinforces the efficacy of its anti-PD-1 therapy pembrolizumab in patients with advanced urothelial (bladder) …
Abbott-St. Jude $25 billion deal close to clearance
November 16, 2016Research and Development, Sales and Marketing Abbott, St. Jude, acquisition
EU antitrust regulators are due to reach a decision on the deal on 23 November that would see Abbott Laboratories …
Janssen’s Crohn’s treatment licensed for UK use
November 16, 2016Research and Development, Sales and Marketing Chrohn's disease, J&J, JJ, Janssen, Johnson & Johnson, Stelara
Janssen, a subsidiary of Johnson & Johnson, has announced that its treatment Stelara (ustekinumab) is now licensed by the European …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
